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POTENTIAL OF UTILIZING SPECIFIC MIRNAS AS BIOMARKERS FOR 
POLYCYSTIC OVARIAN SYNDROME (PCOS) 
NEHA RAMPALLY 
ABSTRACT 
Polycystic Ovarian Syndrome is the one of the leading causes of infertility among 
women who are of child-bearing age. The syndrome’s vast range of phenotypes has made 
it challenging for researchers to not only consistently diagnose but also discover a cure. 
Currently, there are several proposed treatments being looked into, however, much of the 
research focuses on employing promising biomarkers, micro ribonucleic acids 
(miRNAs), that can potentially aid in diagnosis. The four prominent locations of research 
for these biomarkers include: ovarian tissues specifically looking into granulosa cells 
(GC), adipose tissue, follicular fluid, and the serum. My goal is to determine which of 
these areas holds the most promise to diagnose this syndrome in the years to come.  
This study reviewed a large collection of the current polycystic ovarian syndrome 
literature evaluating both reported miRNAs and how viable those would be as potential 
biomarkers to use for the future. The data showed that a majority of these promising 
biomarkers were found in granulosa cells, adipose tissue, and follicular fluid. Although 
there were miRNAs that were deemed promising in the serum, research is still far from 
conclusive in using these miRNAs as biomarkers for diagnosis of polycystic ovarian 
syndrome.  
By comparing the miRNAs selected from each type of location, I was able to 
conclude that miR-21, miR-93, miR-223, and miR-let-7b hold the most promise for the 
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potential to become biomarkers for polycystic ovarian syndrome in the near future. 
Currently, there is a lot of research particularly surrounding these miRNAs and how they 
were shown to have been expressed in statistically significant levels among women with 
the syndrome. However, because of their complexity, miRNAs do not regulate one single 
pathway, it is hard to describe a mechanism that explains the pathophysiology of the 
syndrome. I believe we are still far away from successfully zooming in on one biomarker. 
By determining the most potential biomarker(s), we can focus resources and efforts 
towards finding a better diagnostic tool for this syndrome.  
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Polycystic Ovarian Syndrome, also known as PCOS, is an endocrine and 
metabolic disorder that affects women who are of reproductive-age with a prevalence 
estimated somewhere between 5-10% (Asuncion et al., 2000). There have been studies 
suggesting that it is a multifactorial polygenic disease where the phenotypes very 
significantly different from woman to woman. As illustrated in Figure 1 some common 
signs and symptoms include: hyperandrogenism, ovulatory dysfunction, and polycystic 
ovaries to name a few (B. Chen et al., 2019). As a result of some these symptoms many 
women experience irregular menstrual cycles, infertility, hirsutism, and acne (De Leo et 
al., 2016).  
PCOS has been traditionally viewed as an endocrinlogical issue. However, 
research within the past decade illustrated PCOS has essentially two components: 
endocrine and metabolic. Hyperandrogenemia has been identified as a very useful 
diagnostic for patient populations that are not within the adolescent range (Z. Chen et al., 
2019). Lab tests are performed to measure levels of Luteinizing Hormone (LH), 
testosterone, free androgen index (FAI), and dehydroepiandrosterone sulfate (DHEAS) 
(Stracquadanio & Ciotta, 2015). Typically, physicians measure LH and testosterone 
levels since they are easier to measure. Sometimes measured DHEAS levels are mildly 
elevated along with serum testosterone suggesting that the patient has PCOS. In addition, 
PCOS is also associated with increased risk of developing Type 2 Diabetes, insulin 
resistance, hypertension, oxidative stress, and cardiovascular disease (Y. Zhang et al., 
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2017). Other lab tests are also ordered such as fasting glycemia and insulinemia, because 
more than half the women that are diagnosed with PCOS also develop hyperinsulinemic 
insulin resistance (De Leo et al., 2016). With that said there is no standard diagnostic test 
to properly pinpoint this disease. In addition to the clinical indicators of the syndrome 
there may also be possible pregnancy complications that may arise such as gestational 
diabetes, placental abruption, and preterm birth to name a few (X.-D. Zhang et al., 2013). 
It is important to keep in mind that there is not an effective way at the moment to 
measure the risk of these complications. 
The etiology of PCOS remains widely unknown and the syndrome as a result is 
not well understood.  As of now there are treatment options to alleviate the symptoms, 
however, these treatments do not significantly improve prognosis of PCOS. 
Characteristically, physicians diagnose PCOS as an endocrine disorder and patients are 
prescribed birth controls and progestin therapy (Stracquadanio & Ciotta, 2015). However, 
since research has established that PCOS has a strong metabolic component, physicians 
are also prescribing metformin and statins (Janci et al., 2012). Other medications are 
prescribed to treat the other effects of PCOS such as hirsutism and acne (Table 1). 
Unfortunately, medications alone are sometimes not effective and research has 
demonstrated that keeping track of one’s diet and exercise to maintain a healthy lifestyle 
has shown improvement. In terms of diet, there is no standardized PCOS diet but general 
guidelines to follow are: reducing total calories consumed based on sex, age, and activity; 
favoring complex carbohydrates; increasing fiber, and eating low glycemic index foods. 
Exercise is an important aspect as well because of its effect on weight loss, specifically a 
 3 
reduction in the amount of visceral fat and a reduction to body mass index (BMI) 
(Stracquadanio & Ciotta, 2015). The reasoning behind why visceral fat reduction is good 
is because it is more metabolically active and has been linked to insulin resistance (IR). 
Research studies have shown that women with PCOS who implemented these lifestyle 
changes demonstrated improvement in insulin sensitivity, regular menstrual cycles and 
lower risk of type 2 diabetes and cardiovascular disease (Rocha et al., 2019). 
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Table 1. Treatment of Clinical Symptoms in Patients with PCOS 
























Figure 1. Diagram representing some of the symptoms that can manifest in a patient with PCOS. 
Androgens give rise to hirsutism and acne problems, whereas the estrogen produced by the 
ovaries and the adipose tissue gives rise to infertility and anovulation. AMH = Anti-Mullerian 
Hormone; FSH = Follicle Stimulating Hormone; IGF-1 = Insulin-Like Growth Factor 1; LH = 
Luteinizing Hormone; NAFLD = Non-Alcoholic Fatty Liver Disease; SHBG = Sex-Hormone 





PCOS is a complex disorder which has three different definitions established to 
aid proper diagnosis (Figure 2). The common denominator between all three criteria is 
that of androgen excess. According to the National Institute of Health (NIH) their 
definition includes hyperandrogenism /or hyperandrogenemia and oligo-anovulation, 
whereas Rotterdam encompasses as having the presence of two out of the following three 
features: clinical and/or hyperandrogenism, oligo-anovulation, and Polycystic Ovarian, 
PCO, on ultrasound. The Androgen Excess Society (AES) placed an emphasis on 
hyperandrogenism, and it can be defined principally by clinical and/or biochemical 






Figure 2. PCOS is a complex disease that can present with clinical hyperandrogenism, 
polycystic ovaries, and anovulation. The definition of PCOS is based on three different 
criteria: National Institutes of Health (NIH), Rotterdam, and Androgen Excess Society 
(AES). These three different criteria exclude other disorders that may present with 




Ovaries and adrenal glands in women typically produce similar amounts of 
testosterone. Usually, half of the testosterone comes from direct secretion by ovaries and 
adrenal glands, whereas the other half is made in the periphery via conversion from 
androstenedione (Rosenfield & Ehrmann, 2016). What is unique is that unlike estradiol 
and cortisol secretion, androgen production is not under direct negative feedback in 
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women. This becomes an important factor especially in women who are diagnosed with 
PCOS.  
Many PCOS animal models hypothesize that the upstream Gonadotropin 
Releasing Hormone (GnRH) is hyperactive.  Women who have been diagnosed with 
PCOS typically have higher levels of (LH), which means they have a higher LH pulse 
frequency. The high frequency contributes to ovarian thecal cell hyperplasia, which 
results in increased androgen production and secretion (Rosenfield & Ehrmann, 2016). It 
is important to note that not only is there an overall androgen production increase, but 
also the steroidogenic enzymes needed to make these androgens are also increased in 
PCOS (Xue et al., 2018).  
Another hypothesis points to insulin binding to multiple sites to increase androgen 
levels. As shown in Figure 3, insulin can bind to Insulin-like Growth Factor -1 (IGF-1) 
receptors which can have a positive effect and lead to an increase in theca cells producing 
androgen. With higher insulin levels there is inhibition in the liver to produce Insulin-like 
Growth Factor Binding Protein -1 (IGFBP-1) leading to increased levels of IGF-1 and 
IGF-2, which play an important role in ovarian follicular growth and maturation as well 
as steroidogenesis (Rosenfield & Ehrmann, 2016).  Although the exact relationship is still 
unclear, researchers have confirmed that there is interaction amongst insulin receptors 





Figure 3. Schematic of Major Steroid Biosynthetic Pathways between the theca cell and 
granulosa cell. Luteinizing hormone (LH) promotes the creation of androgen synthesis in the 
theca cell via cholesterol, whereas the Follicle Stimulating hormone (FSH) promotes the creation 
of estradiol in the granulosa cell via the enzyme aromatase. cAMP = Cyclic Adenosine 
Monophosphate; FSHR = Follicle Stimulating Hormone Receptor; LHR = Luteinizing Hormone 
Receptor; PKA = Protein Kinase A; 17HSD1 = 17-Beta Hydroxysteroid Type 1; 17HSD2 = 17-





MicroRNA (miRNA’s) Formation and Function: 
Like many other diseases, researchers within the field of PCOS have shifted gears 
by looking at microRNAs (miRNA) to see if there is a more reliable and effective way to 
diagnose PCOS. MiRNA's are small non-coding sequences that are transcribed from the 
genome via RNA polymerase II or III, forming a stem-loop hairpin structure (Catalanotto 
et al., 2016). Then, a nuclear protein complex that is made up of the Drosha enzyme 
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along with other proteins can cleave the pri-miRNA which results in a pre-miRNA that 
can leave the nucleus and enter the cytoplasm. Afterward, the pre-miRNA encounters 
Dicer, an enzyme that further processes and gives rise to a double-stranded miRNA: 
mature guide and passenger strand (Figure 4). The mature miRNA associates with 
Ribonucleic Acid- Induced Silencing Complex (RISC) and targets the 3’ untranslated 
region of the target mRNA. This results in negatively regulating gene expression at the 
post-transcriptional level either via degrading the target mRNA or inhibition of 
translation. This is critical because many miRNAs’ have important regulatory functions 
in many processes ranging from cell proliferation to apoptosis (Deswal & Dang, 2020). 
The next logical question to ask is how do miRNAs regulate gene expression? 
One proposed mechanism is that the nuclear complex RISC can mediate post-
transcriptional gene silencing with miRNA in the nucleus as well as the cytoplasm. 
Another approach is that miRNAs can interact with the promoter region in association 
with the Ago protein and this can either lead to activation or suppression depending on 
the location of the target region and the epigenetic status (Hou et al., 2019). Finally, 
activation can be interrupted via miRNA’s seed region by either being deleted, mutated, 
or when the enhancer locus is deleted. Enhancers are short regions of DNA that can bind 




Figure 4. Schematic of miRNA synthesis and function in animals. The pri-miRNA is transcribed 
by RNA Pol II, then cleaved by Drosha-DGCR8 to produce pre-miRNA. Once the pre-miRNA is 
out in the cytoplasm it is further processed via Dicer upon which a mature miRNA is produced. 
Then, the mature miRNA combines with miRISC that typically results in silencing of the gene of 
interest. Dgcr8 = Digeorge Syndrome Chromosomal Region 8; miRISC = micro RNA Induced 
Silencing Complex; TRBP = Transactivation-Responsive RNA Binding Protein. (Hajarnis et al., 
2015) 
Subsection One: 
Preliminary research in this field discovered that women diagnosed with PCOS 
have altered levels of microRNAs (miRNA) that can be found within many places 
throughout the body such as granulosa cells, theca cells, adipose tissue, follicular fluid, 
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and serum (B. Chen et al., 2019). In addition, miRNAs have been shown to play a role in 
the activation of primordial follicles, follicle development, oocyte maturation, and 
ovulation (Das et al., 2008). These miRNAs were shown to be found either encapsulated 
in microvesicles or free-floating. The hope is that by identifying some of these miRNA’s 
we gain a better understanding of PCOS and they can potentially act as noninvasive 
biomarkers and become effective therapeutic targets in trying to better treat and cure 
PCOS (Atiomo et al., 2009).  
As mentioned previously, there are many ways miRNA can affect us, and trying 
to understand which specific miRNAs are involved in the pathogenesis of PCOS can 
provide insight into discovering new treatment therapies (Liu et al., 2018). Hence, it 
would be ideal to discuss the physiology of PCOS and discuss different levels of 
expression of these miRNAs that can disrupt normal processes and lead to PCOS 
symptoms.  
The following few paragraphs will provide a brief summary of how researchers 
are trying to identify where viable biomarkers for PCOS can be found. Numerous studies 
concurred about how hyperandrogenism and insulin resistance are amongst the common 
symptoms that many women have when diagnosed with PCOS. Rationally, it made sense 
to look at cells/tissues that are involved in these important processes and observe 
miRNAs that are significantly different in women diagnosed with PCOS versus those 






Granulosa cells (GC) are critical to oocyte development because they provide 
nutrients and regulate the growth of oocytes. It is important to highlight that beyond 
helping oocytes grow, one of their major functions is the production of sex steroids as 
well as various growth factors. The production of sex steroids is triggered by Follicular 
Stimulating Hormone (FSH) from the anterior pituitary gland which stimulates the 
granulosa cells to convert androgens into estradiol via the enzyme aromatase (Figure 5). 
Also, granulosa cells are responsible for producing FSH receptors.  
Artimani et. al (2015) concluded that abnormal folliculogenesis observed in 
PCOS occurs when there is a reduction in the number of genes related to estrogen and 
progesterone nuclear receptors expressed in GCs. As mentioned previously, the 
interaction between oocytes and GCs is important to the normal development of follicles. 
Specifically, the study was able to illustrate that the Estrogen Receptor β (ERβ) is 
predominantly expressed within GCs, which supports the hypothesis that these receptors 
are important for control of ovarian follicles. However, other studies suggest that there 
was a higher expression of ERα in GC cells (Jakimiuk et al., 2002). Researchers further 
probed and found that women diagnosed with PCOS have lower levels of ERα which can 
potentially lead to abnormal folliculogenesis (Jakimiuk et al., 2002).  
Since these receptors are expressed within GC cells, researchers further 
questioned how to identify the miRNAs involved (Das et al., 2008). One of the 
conclusions that they arrived at is depending on the stage of oocyte development, there 
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are different levels of miRNA that were expressed. Many assays were performed and 
there was one miRNA that was deemed significant: miR-145 (Cai et al., 2017).  
 
Theca Cells: 
There is strong evidence that the granulosa and theca cells have to communicate 
with each other to produce estrogen that plays an important role in fertility (Magoffin, 
2005). The theca cells are located in the ovary and are highly differentiated. The main 
function of these cells is to produce steroid hormones such as androstenedione (Figure 5). 
For theca cells to produce the right amount of hormones they are under the control of LH 
through stimulation of the cAMP signaling pathway. The reason why this important is 
because one of the key clinical manifestations in PCOS is hyperandrogenism. 
According to Wood et. al (2004) experiments demonstrated there was an 
increased amount of mRNA related to the activity of the P450scc enzyme, which plays a 
role in converting cholesterol to pregnenolone and this is the first step in the process of 
steroidogenesis. Additionally, this first step is the rate-limiting step in steroid production. 
Also, there were increased levels of CYP17 promoter (Rosenfield & Ehrmann, 2016). 
The function of CYP17 is to hydroxylate 17α of pregnenolone to yield 17α-OH 
pregnenolone and cleavage of the c17, 20 bonds to yield the androgens DHEA or 
androstenedione.  
Researchers further postulated that since these enzymes are important for steroid 
production, there might be miRNAs that can affect their production. Li et al. (2016) have 
identified possible miRNAs that may impact the functions of these enzymes. Their 
14 
research focused on GATA6 and it is an important androgen-producing gene that 
stimulates CYP17 promoter. Results showed that miR-92a targets GATA6 and women 
with PCOS were shown to have lower levels of miR-92a. This ends up causing an 
increase in GATA6 expression and thus an increase in the activity of the CYP17 
promoter. 
Figure 5. Theca cells produce the androgens, whereas the granulosa cells convert the 
androgens into estrogens. Estrogens then stimulate the growth of the granulosa cells and they 
acquire LH receptors as a result of this process. A = Androgens; E = Estrogens; FSH = Follicle 




Adipose tissue is seen as a place for storing and releasing energy to make sure the 
body’s metabolic needs are met (Figure 6). This is regulated via insulin binding to its 
receptor on the adipocyte which triggers an exocytosis reaction of GLUT-4 to the plasma 
membrane and allows glucose to flow inside the cell. In turn, glycolysis is activated and 
produces Adenosine Triphosphate (ATP). Also, there is increased lipid synthesis that 
allows the storage of fat droplets. Lastly, there is an increase in protein synthesis to make 
lipoprotein lipase (LPL) to breakdown the very low-density lipoprotein (VLDL) or 
chylomicron coming from the liver so they can be repackaged upon entering the 
adipocyte.  
Women who have been diagnosed with PCOS, especially those women who are 
overweight or obese, are 50-70% more likely to also be diagnosed with IR (Cai et al., 
2017). Researchers have concluded that there is a link between IR & PCOS but the 
cellular mechanisms have not been well identified and are an active area of research. IR 
is when the bloodstream has excess glucose and that reduces the function of cells to 
uptake and use that glucose for energy. As a result, the pancreas ends up producing more 
insulin to help glucose enter cells.   
Chen et al. (2013) collected data where they compared women who had PCOS 
with and without IR.  They concluded that miR-93 was found in adipocyte tissue 
irrespective of IR, however, miR-223 was found in women that had IR. This led the 
researchers to further hypothesize higher expression levels of both miR-93 & miR-223 
16 
decrease GLUT-4 protein in adipocyte tissues. As a result, providing a potential 
explanation of how PCOS can affect IR in adipocytes. 
Figure 6. Schematic of an adipocyte when there is high levels of glucose detected in the blood 
stream. The adipocyte upon sensing this information performs many mechanisms such as: 
increasing the rate of glycolysis to produce Adenosine Triphosphate (ATP) to sustain lipid 
synthesis. Lipid synthesis is important as it packages lipid droplets so the body has stores of 
energry available for future use. Lastly, there is increased protein synthesis directed towards 
making the enzyme lipoprotein lipase (LPL). GLUT-4 = Glucose Transporter Type 4; TG = 




Rosenfield and Ehrmann (2016) have briefly summarized how granulosa and 
theca cells are imperative to the proper growth and function of the ovary. An additional 
compartment to focus on finding probable miRNA biomarkers is follicular fluid. The 
follicular fluid is produced from granulosa and theca cells and it serves as an important 
microenvironment to allow proper growth and development of oocytes (Butler et al., 
2019).  
Follicular fluid is not however just made of only growth factors, hormones, and 
nutrients to allow the oocyte to mature, but according to Revelli et al. (2009), it also 
includes anti-apoptotic factors, proteins, and nucleotides (Figure 7). There is active 
research being performed to identify possible biomarkers within this fluid, however, there 
is little consensus on the research. For example, Roth et al. (2014) reported that miR-9, 
miR-32, & miR-135a were found at high levels in PCOS follicular fluid. Upon further 
examination, researchers found that these miRNA biomarkers were associated with 
carbohydrate metabolism: insulin receptor substrate 2 & interleukin 8 (Cirillo et al., 
2019).  
Another study illustrated that miR-132 and miR-320, which have been closely 
associated with estradiol secretion, were expressed at low levels in women with PCOS 
(Delitala et al., 2017). On the contrary, Ling et al. (2009) showed that there were high 
expressions of miR-320. Researchers from this study hypothesized miR-320 could 
suppress the production of estrogen which might explain the hyperandrogenemia in 
PCOS. Researchers have determined that a common theme among women diagnosed 
with PCOS is the miRNAs are involved in the regulation of steroid synthesis. 
18 
Figure 7.  A schematic representation of an oocyte with information of what can be found in the 
follicular fluid. The follicular fluid is an amalgamation of growth factors, hormones, nutrients, 
apoptotic factors, proteins, nucleotides, metabolites, and vitamins.  
Extracellular Fluid: 
Imagine the scenario where researchers have discovered viable, accurate, and 
stable miRNAs as possible markers for PCOS, but having to get to a theca or granulosa 
cell seems invasive and difficult. Whereas if researchers were able to find just as 
comparable biomarkers in a more accessible compartment of the body to diagnose 
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whether the patient has PCOS or not. The extracellular compartments of the body is an 
important aspect to consider when thinking long term. 
Surprisingly, miRNAs compared to the longer mRNAs were observed to be more 
stable due to encapsulation into microvesicles and association with protein complexes 
(Dufourd et al., 2019). So, why aren’t researchers solely focusing on extracellular 
miRNAs? According to Kirschner et al. (2011) it has to do with collecting the blood and 
processing it. This poses a hemolytic threat and ends up degrading the miRNAs in the red 
blood cell. The shortcoming of this research is that only a few select miRNAs have been 
selected to study and we do not know whether this applies to every miRNA in the 
bloodstream. Despite shortcomings, numerous studies have shown that there are 
distinctive levels of miRNA expression present in the serum of PCOS patients (Arancio 
et al., 2018).  
 
Serum: 
As previously mentioned, hyperandrogenemia is a common feature of PCOS. 
Song and colleagues (2015) have determined that the reduced levels of miR-592 were 
associated with high levels of LH/Chorionic Gonadotropin Receptor (LHCGR). This is 
an important relationship because this receptor plays a role in how patients develop 
hyperandrogenemia. Other studies have shown that there were certain miRNAs that were 
negatively correlated with serum testosterone such as miR-146a, whereas miR-21, miR-
27b, and miR-155 were positively correlated (Hou et al., 2019).  
Women diagnosed with PCOS were also found to be more at risk of developing 
insulin resistance and diabetes later. Another study compared patients who have damaged 
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glucose breakdown versus those who did not, and found that there were three miRNAs’ 
that stood out: miR-122, miR-193b, and miR-194 were found to have increased 
expression levels (Kong et al., 2011). Besides, the listed miRNA’s, Long et al. (2014) 

















PUBLISHED STUDIES  
 
Previous Studies: 
As a result of this brief introduction to some possible target sites a common theme 
was observed: many of these miRNAs that are discovered as possible biomarkers in some 
way affected carbohydrate metabolism and the steroidogenic synthesis pathway 
(Lerchbaum et al., 2014). These results correctly map onto clinical manifestations that so 
many women have when diagnosed with PCOS. Furthermore, it is interesting to see that 
the downstream targets of these miRNAs are associated with proteins that have important 
roles in metabolism and steroid synthesis (De Leo et al., 2016).  
The next part of the thesis will focus on specific miRNAs which I will describe 
the mechanism they act by, their role, association with other proteins, and 
viability/accessibility as a biomarker. The latter is what defines a good biomarker from a 
bad biomarker (Holland, 2016). Ultimately, physicians want to be able to use a biomarker 




Undoubtedly, granulosa cells are necessary for sustaining follicular growth and 
endocrine signaling to other tissues as well as synthesis of estrogen. Typically, GCs try to 
maintain a balance of follicular growth and death. When GCs are programmed for cell 
death, they stimulate and form atresia follicles (Cai et al., 2017). However, a multitude of 
studies have confirmed that GCs contribute to the abnormal follicle growth seen in 
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PCOS. According to Das et al. (2008), lower apoptotic rates and higher proliferation rates 
were seen in GCs from patients that have PCOS. Researchers realized that these cells 
might not only provide insight into the possible identification of biomarkers but also 
present as an avenue for the potential treatment of PCOS. miR-145 was isolated from 
GCs in women with and without PCOS, and many other studies focused on this target as 
well (Naji et al., 2018).  
Cai et al. (2017) studied the effect of miR-145 on cell proliferation and its 
mechanism of action. In addition, identifying what proteins miR-145 might be associated 
with could lead to the effect it has on GCs. The researchers started by trying to establish 
how miR-145 suppresses cell proliferation in human GCs. Naturally, the next line of 
thought would be how miR-145 is promoting cell apoptosis. Utilizing an algorithm based 
on mircoRNA.org-Targets and Expression, Cai and colleagues (2017) were able to 
predict that IRS1 might be a potential target.  
IRS1, also known as Insulin Receptor Substrate-1, plays a role in providing 
signals from insulin and insulin-growth factors receptors in critical pathways such as 
PIK3/Akt and Erk/MAPK (Martini et al., 2014). Both pathways are involved in essential 
processes that affect glucose metabolism, apoptosis, and cell proliferation. To determine 
whether IRS1 plays a role in GCs a knockout experiment was performed (Cai et al., 
2017).  When researchers silenced IRS1 they found that GCs had a lower cell survival 
rate. This demonstrated that IRS1 could inhibit GC proliferation.  What role does miR-
145 have on IRS1? To find out a luciferase reporter assay, QRT-PCR, & Western blotting 
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was performed. The results showed that the IRS1 is a target of miR-145 and that it ends 
up binding to the 3’-UTR region and prevents expression of IRS1 (Cai et al., 2017).   
As mentioned previously, Erk/MAPK signaling pathways are important for GCs. 
A plausible mechanism of how miR-145 causes suppression of cell growth might be: 
suppressing IRS1 which leads to the Erk/MAPK pathway not being activated (Naji et al., 
2018). miR-145 could serve as a potential avenue of therapy with patients who have 
PCOS, however, miR-145 is located in GCs, so trying to obtain samples might be 
considered invasive for many patients, but this alone is not a reason to eliminate miR-145 
and other biomarkers that are being found.  miR-145 shows promise and other 
researchers like Naji and colleagues (2018) have also arrived at a similar conclusion that 
miR-145 levels are starkly reduced but also have managed to find another potential 
target, miR-182.  
To deem a biomarker credible, it needs to have three characteristics: analytical 
validation, clinical validation, and clinical utility (Holland, 2016). While research with 
miR-145 is hopeful, researchers agree that a more thorough mechanism as to how this 
biomarker functions needs to established. Thus far, research has provided us with a basic 
outline of how miR-145 acts and what it does. Once, a proper mechanism has been 
established it is logical to assess the validity, accuracy, and precision of miR-145 to be a 






miR-200b & miR-200c: 
Other miRNAs like miR-200b and miR-200c have received a lot of attention as 
potential biomarkers, but for a different disease (Belgardt et al., 2015). Numerous studies 
focused on how these miRNAs were involved in endometrial cancer and nasopharyngeal 
carcinomas, while it was relatively limited in PCOS (Sirotkin et al., 2009). However, He 
and colleagues (2019) realized that these miRNAs might play a role in the development 
of PCOS.  
 
Like miR-145, miR-200b and miR-200c have been demonstrated to effect GC 
proliferation as well, but the mechanism is different (Dou et al., 2013). Researchers 
showed that miR-200b and miR-200c might also play an important role in the 
dysregulation of GCs within PCOS (He et al., 2018). He et. al (2019) found that there are 
two significant forms of miR-: miR-200b and miR-200c.  
He and colleagues (2019) further explored the underlying mechanism of how 
miR-200b and miR-200c can effect GCs. These researchers employed a set of techniques 
similar to Cai et al. (2017) to try and identify the mechanism of miR-200b and miR-200c. 
First, they had to demonstrate that both miRNAs suppressed GCs proliferation. The team 
utilized KGN cells instead of GCs because these cells come from a steroidogenic human 
granulosa-like tumor cell line. Through the process of transfection, researchers inserted 
miR-200b and mR-200c mimics and, compared to the control, the results demonstrated 
that there was an overall inhibition of KGN cell proliferation. The next step was to 
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identify any possible gene targets by using TargetScan, researchers found PTEN to help 
further elucidate the mechanism by which miR-200b and miR-200c might work.  
PTEN, also known as phosphatase and tensin homolog, is a gene that encodes 
instructions for making an enzyme that acts as a tumor suppressor, which is essential in 
regulating cell division by keeping cells from growing or dividing too rapidly Genetics 
Home Reference, 2015). The PTEN enzyme is part of the signaling pathway that signals 
cells to stop dividing and triggers cells apoptosis. Evidence suggests that this enzyme also 
helps control cell movement, the adhesion of cells to surrounding tissues, and the 
formation of new blood vessels (Genetics Home Reference, 2015). These functions help 
to avert uncontrolled cell growth that has the potential to form tumors. 
According to the results, a miR-200b inhibitor led to increased levels of PTEN 
mRNA, whereas the miR-200b mimic led to a decrease in the levels of PTEN mRNA (He 
et al., 2019). The same results were also seen with the miR-200-c mimic as well as the 
inhibitor. He et al. (2019) then proposed that PTEN is a target of both, miR-200b as well 
as miR-200c. Other researchers have also observed that overexpression of miR-200b and 
miR-200c might play a role in contributing to insulin resistance, which is characteristic of 
PCOS (O’Reilly et al., 2014). This study, however, was not able to establish a thought-
out mechanism. All we learned from this study was that PTEN is a potential target, 
however, PTEN is located in a lot of tissues throughout our body. In trying to figure out 
whether these miRNAs would be probable biomarkers, the first thing that comes to mind 
is how can we isolate the target located specifically GCs and not affect other cells along 
the way.  
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Akin to miR-145, miR-200b & miR-200c more research needs to be performed to 
see if these are valid biomarkers to utilize and diagnose patients with PCOS. There needs 
to be a statistical difference that shows that women with PCOS have increased expression 
of these miRNAs. Even prior to that, a more elucidated mechanism needs to be proposed 
to better understand how these miRNAs contribute to the abnormal folliculogenesis that 
is seen in patients with PCOS.  
 
miR-93: 
Based on a multitude of studies that have been demonstrated, miRNAs have been 
discovered that are not limited to target one mRNA (Liu et al., 2018). As a result, one can 
deduce that a miRNA does have the potential to cause multiple diseases. On this basis, 
Jiang et al. (2015) studied miR-93, which has been implicated in ovarian cancer, but also 
in steroidogenesis. Based on PCOS diagnostic criteria hyperandrogenism is a symptom, 
so it makes sense to see if miR-93 might be involved in contributing to ovarian 
abnormality and trying to determine the mechanism of increasing granulosa cells 
proliferation.   
Jiang et al. (2015) have chosen to study multiple miRNAs using similar 
techniques described in previous experiments. Jiang and colleagues (2015) were able to 
see a statistically higher level of miR-93 expressed among women with PCOS compared 
to control. This was further compared to the target gene predicted by bioinformatics 
which yielded the same result. Jiang et al. (2015) utilized flow cytometry to identify what 
phase of the cell cycle miR-93 had a potent role on. The results demonstrated that there 
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was an increased proportion of cells that were in the S-phase. To further support this 
result, an miR-93 inhibitor was transfected into cells and this illustrated a decreased 
proportion of cell in the S-phase.  
To better explain how miR-93 promotes growth, Jiang and colleagues (2015) 
utilized starBase2.0 and the most probable target gene was hypothesized to be CDKN1A, 
a cyclin-dependent kinase inhibitor. This gene encodes for a protein that inhibits the 
activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and 
functions as a regulator of cell cycle progression at G1 (CDKN1A Gene-NCBI, 2020). 
This gene is controlled by the tumor suppressor protein, p53 (Figure 8). p53 plays an 
important role in the initiation of the cell cycle arrest pathway to either repair damages or 
undergo apoptosis. In addition, this protein has a regulatory role in S phase DNA 
replication and DNA damage repair. p53 is reported to be cleaved by CASP3-like 
caspases, which leads to activation of cyclin-dependent kinase2, and is important to 
stimulate apoptosis following caspase activation (Kanapathipillai, 2018).  
To observe the effect miR-93 would have on CDKN1A: KGN cells were 
transfected with miR-93 mimics and the results demonstrated a decrease in CDKN1A 
levels and therefore stimulated cell proliferation.  Whereas, miR-93 inhibitors showed 
increased levels of CDKN1A and inhibited cell growth (Jiang et al., 2015). Logically, 
high levels of miR-93 were correlated with low levels of CDKN1A mRNA. This is 
strong evidence that CDKN1A is a direct target of miR-93.  Even though previous 
research established that miR-93 had played a major role as a tumor promoter implicated 
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in certain cancers. This study was able to successfully demonstrate that it not only has a 
role as tumor promoter, but also the potential to be a granulosa cell promoter.  
The hope of this research was to provide a new perspective and a possible 
explanation on how the dysregulation of granulosa cells can contribute to PCOS (Miles et 
al., 2012). Despite its strong candidacy, miR-93 has not moved forward as a potential 
biomarker. The reason is two-fold: 1) the sample size in this study was very small (N=24) 
and that is not enough evidence for reproducibility which is needed in a diagnostic test 
and 2) like most of the miRNAs that was seen thus far there has not been a well-












Figure 8. p53 is inactive when it is bound to mouse double minute 2 (mdm2). When there is DNA 
damage, stress, or shock, there is a pathway that is triggered that leads mdm2 to dissociate from 
the p53 protein. The p53 protein then becomes activated and will signal the cell cycle to arrest to 









Research validated that GCs are a source of finding plausible miRNAs to utilize 
for diagnosing PCOS. However, it provides a limited perspective of PCOS because its 
clinical manifestations are beyond the ovary. PCOS also impacts the body’s metabolism. 
(Bagge et al., 2012). Peng et al. (2014) postulated women with PCOS that are either 
overweight or obese are at a more increased risk of developing diabetes, insulin 
resistance, hypertension, oxidative stress, and cardiovascular disease. Rationally, 
researchers explored the adipose tissue to discover another source of potential miRNAs 
that can be utilized (Ezeh et al., 2020).  
Unlike other studies that chose to look at a few select miRNAs and find a possible 
mechanism, Qin and colleagues (2019) took on an additional task. They discovered a 
potential miRNA and hypothesized that Dicer may play a role in adipocytes and obesity. 
Dicer is an enzyme involved in cleaving the pre-miRNA into short double-stranded RNA 
fragments. Further research has discovered that Dicer and many miRNAs play a 
regulatory role in biological processes associated with obesity such as adipocyte 
differentiation & lipid metabolism. Researchers postulated how obesity has an effect on 
women with PCOS and that obesity may very well be involved in the etiology of PCOS 
(Murri et al., 2013). Thus, the reasoning behind to study Dicer as well as miR-223.  
Qin et al. (2019) performed experiments utilizing similar techniques as other 
researchers in the field. The results demonstrated that the expression of Dicer is reduced 
in those with IR. The results further revealed that the adipocytes in women with PCOS 
and IR showed decreased levels of Dicer.  miR-223 is important because Qin and 
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colleagues (2019) determined that it plays a vital role in the differentiation of adipocytes. 
This was illustrated when miR-223 resulted in low expression of genes related to 
differentiation in adipocytes.  
Chuang et al. (2015) studied miR-223 because it has been implicated in many studies as 
being abnormally expressed especially in PCOS women who have IR (Dou et al., 2013). 
As of now, research is still being conducted to discover how abnormal expression of 
miR-223 plays a role in the dysregulation of metabolism among PCOS women and IR. 
Using techniques such as western blotting and a luciferase reporter assay several 
observations were noted (Chuang et al., 2015). The most significant observation was 
women who were diagnosed with IR had higher levels of miR-223 compared to their 
counterparts. Chuang and colleagues (2015) also discovered that high levels of miR-223 
inhibited glucose uptake stimulated by insulin in adipocytes. Understanding how glucose 
can enter the adipocyte is important and this led researchers to postulate that GLUT4 
protein is decreased (Lu et al., 2010). Chuang et al. (2015) were also able to verify this 
through experimentation.  Even though protein levels of GLUT4 were decreased, the 
mRNA levels were not affected. This allows us to conjecture that miR-223 may regulate 
GLUT4 expression by binding to the 3’-UTR of the mRNA. Ultimately, this research 
pointed out that miR-223 may have a role in explaining IR, but it was irrespective of 
PCOS status.  
Most of the current research agrees that miR-223 is implicated in IR, but the 
mechanism is still unknown (Y. Zhang et al., 2017). This may be because miRNAs have 
a multitude of targets they can act on. There needs to be strong evidence that miRNA-223 
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does play a role in the etiology of PCOS and this is done by establishing a mechanism 
and increasing the sample size of the studies. Hitherto, studies at most had 30 subjects 
and by increasing the sample size, the results that come out of the study are statistically 
more powerful. This leads us a step closer in trying to figure out the complex way the 
PCOS affects women and potentially not only discovering biomarkers but also a 
therapeutic agent.  
 
 
miR-25 and MCM7: 
 
As noted earlier, 60-70% of women with PCOS have been diagnosed with IR and 
puts them at risk for acquiring other diseases such as type 2 diabetes and cardiovascular 
disease (Ezeh et al., 2020). Research has not found a clear mechanism to explain how IR 
is related to PCOS. As a result, studies have been published that postulates adipose tissue 
is an area to look for potential dysregulation (Delitala et al., 2017). Scientists have 
pointed out that PCOS women have problems with glucose transport, GLUT4 production, 
and lipolysis (Lu et al., 2010).  
Previously miR-93 was thought to affect granulosa cells proliferation. However, 
Wu et al. (2014) demonstrated that high levels of miR-93 directly inhibit GLUT4 
expression. This study observed how miR-93 affects its target gene, maintenance-
deficient 7 (MCM7), and other miRNAs like miR-25 to understand how regulation works 
in adipocytes. Some observations that were deduced are intriguing and may provide some 
perspective. miR-25 was expressed at high levels in subjects with IR irrespective of 
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PCOS (Wu et al., 2014). Even though researchers found that miR-25 levels were higher 
in adipocytes in subjects with PCOS and IR it was not statistically significant.  
Now we turn towards the other target: MCM7 gene. The protein is synthesized via 
transcription and translation contributes to the initiation of DNA replication (Cao et al., 
2015). Logically, if there are high levels of miR-93, then there would be low levels of 
MCM7. Wu et al. (2014) discovered a similar result: a negative correlation was shown 
between MCM7 and miR-93. MCM7 levels were lower in adipocytes in women with 
PCOS. This suggests that miR-25 and MCM7 are regulated through different regulatory 
pathways. This may be due to a couple of reasons: the stability of the transcript or further 
miRNA post-transcriptional regulation (Miles et al., 2012). Due to these inconsistencies, 
there is no strong enough evidence provided that would indicate miR-25 plays a 
regulation in the development of IR.  
Unfortunately, miR-25 does not have much research published that suggests it 
would be a viable biomarker in PCOS. Further studies performed to examine the role of 
miR-25 and how it regulates IR in the etiology of PCOS. Wu et al. (2014) presented an 
interesting opportunity to study miR-25, even though their research indicated miR-25 did 
not reflect the same expression levels of MCM7. What if the attention was turned 
towards identifying plausible RNA binding proteins (RBP)? 
RBPs are proteins that bind to double or single-stranded RNA and form highly 
intricate complexes (Hentze et al., 2018). RBPs play an important in post-transcriptional 
processing which can affect mRNA transcription, transport, translation, and degradation. 
In addition, RBPs aid in determining the function of miRNAs. Future studies should be 
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focused towards studying the targeted miRNAs along with trying to identify their 
associated RBPs to gain a better understanding of how miRNAs can regulate certain 
mRNAs (Hentze et al., 2018). The challenge I surmise is a large number of these RBPs 
have not been categorized and researchers might have to characterize these newly 




 Studies demonstrated that the metabolic component of PCOS plays an influential 
role in increasing the risk of developing diabetes, metabolic syndrome, and IR (Carletti et 
al., 2010). Researchers theorized a pathway that is continually being fed where excess 
levels of androgens favor visceral fat which stimulates ovarian and adrenal cells via 
autocrine, paracrine, or endocrine signaling to induce hyperinsulinemia (Lerchbaum et 
al., 2014). Evidence has strongly indicated that we start targeting obesity, visceral 
adiposity, and IR to reduce the signs and symptoms of PCOS (Peng et al., 2014). 
Therefore, developing a better understanding of the mechanism that lead to PCOS can aid 
in identifying novel diagnostic targets.  
miR-21 has been associated with hormone metabolism, adipogenesis, and insulin 
signaling(Jiang et al., 2015). Murri et al. (2013) performed a series of experiments to 
determine the biological function and regulatory role that miR-21 might play in PCOS. 
One of the experiments performed looked at obesity and androgen excess to see which 
miRNAs were statistically significant. The results indicated there were four miRNAs: 
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miR-21, miR-27b, miR-103, and miR-155. Then, Murri and colleagues (2013) were able 
to identify possible target genes for miR-21 utilizing TargetScan, MicroCosm, and Pictar. 
Based on the target genes that were analyzed miR-21 affects various biological functions 
like carbohydrate metabolism, lipoprotein synthesis, energy reserve metabolic process, 
and insulin signaling pathway (Naji et al., 2017). Their results further illustrated that 
there was a negative correlation between obesity and expression levels of miR-21. 
Logically, future studies should look at obesity and how it plays a role in giving rise to 
metabolic dysfunction. 
Kim et al. (2009) performed a series of experiments to determine the function of 
miR-21and arrived at a similar conclusion: obesity is a metabolic disorder that plays a 
definite role in the metabolic abnormalities observed in PCOS. Furthermore, cell 
communication is a regulated process and it has been reported to be altered in obesity and 
PCOS. Other studies concurred that the communication between inflammatory and 
metabolic cells contributes to metabolic dysfunction (Cirillo et al., 2019) (Dou et al., 
2013). To better understand obesity, the researchers examined adipocyte differentiation 
with human-derived adipose-derived stem cells (hASCs) to see whether these cells are 
regulated by miR-21 and if they can give rise to metabolic diseases. After performing 
PCR analysis and a northern blot analysis with a miR-21 probe the results demonstrated 
increased levels of miR-21 expression. Employing TargetScan Kim et al. (2009) were 
able to identify on the target gene, TGFBR2.  
These results were confirmed by Naji et al. (2017) and they performed a study to 
see whether TGFBR2 downregulated TGF-β and examined the overall effect it had in 
 
35 
adipocytes. The results demonstrated low levels of SMAD3 which led to increased 
adipocyte differentiation and is strong evidence that SMAD3 plays a role in adipocyte 
differentiation. This novel correlation of SMAD3 along with previous studies illustrating 
the role of TGFBR2 is strong evidence that the TGF-β signaling pathway modulates 
adipocyte differentiation (Qin et al., 2001). As a result, this provides a potential 
mechanism in understanding obesity and how these results can be extrapolated to 
pinpoint the etiology of PCOS.  
 Obesity is one aspect to better understand the metabolic component of PCOS. 
Since obesity is controlled by various genes this leads to a variety of symptoms in women 
with PCOS (Wang et al., 2020). This can lead to many etiological mechanisms to 
manifest and sometimes inconsistencies in the data. Prior to deeming miR-21 a credible 
biomarker more studies need to be performed to better elucidate what mechanisms in 
PCOS are affected. Thus far, research has focused mainly on the TGF-β pathway, but I 
believe to gain a better-understanding the MAPK signaling pathways and the insulin 





PCOS is a complex syndrome that presents with abnormal follicular development 
and growth (Eisenberg et al., 2017).  As a result, this ends up affecting the fertility of 
women, because their bodies fail to release eggs properly and on time. Scientists focused 
on looking at cells that directly impact these processes such as GCs and theca cells. This 
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led researchers to discover potential miRNAs as biomarkers but also paved the way to 
look outside the cells and see that the environment of the oocytes plays an equally 
important role. The follicular fluid is an important microenvironment because depending 
on the types of proteins, lipids, and metabolites that are present, it provides vital 
information about the state and quality of the oocyte (Martinez et al., 2018). Researchers 
have identified that some of these proteins/metabolites have been associated with 
reproductive disorders.  
 
Other research has established that miRNAs have been found in areas of the 
ovarian tissues, Sang et al. (2013) hypothesized that relevant miRNAs might be present 
in follicular fluid and aid in explaining the pathophysiology of PCOS. Sang and 
colleagues (2013) used follicular fluid and performed techniques such as electron 
microscopy, RNA isolation, and miRNA array and profiling to grow and transfect cells to 
identify possible miRNAs. Sang et al. (2013) found many miRNAs but one stood out: 
miR-320. When they compared expressions of the various miRNAs between PCOS 
women and their controls, there was a statistical significance for both miR-132 and miR-
320. Both miR-132 and miR-320 demonstrated to be lower in subjects with PCOS. By 
transfecting KGN cells, Sang et al. (2013) determined that miR-320 played a part in the 
regulation of hormonal secretion, specifically estradiol secretion.  
Many studies were published to further aid in identifying a possible mechanism of 
how miR-320 affects PCOS. miR-320 has widespread biological effects as it regulates 
many molecules, but of particular interest is endothelin (ET-1) (Zhang et al., 2017). ET-1 
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is a protein produced by endothelial cells and is involved in cell mitosis (Vignon-
Zellweger et al., 2012). Rashad et al. (2019) investigated the relationship present among 
PCOS women by comparing expression levels of miR-320 and ET-1. The results 
illustrated among PCOS subjects that also had IR, miR-320 was expressed at low levels, 
whereas ET-1 was expressed at high levels. In addition, PCOS subjects with IR also 
showed high levels of fasting serum insulin (FSI) and Homeostatic Model Assessment of 
Insulin Resistance (HOMA-IR) levels. These results were largely concordant with other 
studies published studying the expression levels of miR-320 (Sørensen et al., 2016). 
Emerging evidence postulates that miR-320 acts through its target ET-1 which inhibits IR 
in PCOS women via IRS-1, insulin receptor substrate 1. The protein, IRS-1 regulates the 
Erk 1/2 signaling pathway that ultimately plays a role in follicular growth and maturity 
(Figure 9). 
In conclusion, there is strong evidence supporting that miR-320 has the potential 
to be a plausible biomarker for PCOS. There is still uncertainty with regards to the 
mechanism and I agree that there need to be more experiments directed towards how 
miR-320 plays a role in PCOS.  However, these studies alone are not enough and further 
analysis is needed to deduce whether miR-320 is a credible biomarker. Future studies that 
focus on evaluating the prognostic, diagnostic, and therapeutic significance need to be 
performed in a larger sample size (Rupaimoole et al., 2011).  
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Figure 9. Diagram showing the IRS1 signaling pathway. When the tyrosine kinase receptors 
(TKR) are activated this attracts IRS1 to bind and there are other signaling molecules and 
effectors called to aid in important biological processes such as proliferation and cell survival. Akt 
= Protein Kinase B; Erk1/2 = Extracellular Signal-Regulated Kinase 1/2; Grb2 = Growth factor 
receptor-bound protein 2; MAPK = mitogen-activated protein kinase; mTOR = mammalian target 
of rapamycin; PI3K = Phosphoinositide 3-kinase; p70S6K = ribosomal protein S6 kinase; SHP2 = 
Src homology 2-containing phosphotyrosine phosphatase; SOS = Son of Sevenless. (Machado-
Neto and Traina, 2013). 
miR-let-7b: 
As indicated earlier, experiments were performed comparing PCOS women and 
controls in order to identify good biomarkers. Results illustrated different expressions of 
a variety of miRNAs in follicular fluid among women with PCOS. Thus, representing a 
promising approach to identify new biomarkers. It is worth reiterating that the follicular 
fluid is not just an environment that provides support for the oocytes to grow and mature, 
but also serves as a predictive factor of the quality of the oocyte (Scalici et al., 2016). 
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However, just like the GCs, adipocytes, and other ovarian tissues the miRNAs that have 
been found and explored are complex. It is hard to pinpoint one mechanism and explain 
how they regulate pathways which ultimately lead to PCOS.  
Another potential miRNA that researchers have come across is miR-let-7b. 
Scalici et al. (2016) compared the expression of miRNAs in follicular fluid with women 
with PCOS and controls. Three miRNAs were shown to be statistically significant: miR-
140, miR-let-7b, & miR-30a. These results were further analyzed via a multivariate 
analysis. This study highlighted the expression of miR-140 and miR-let-7b were lower 
compared to miR-30a which was higher. The three miRNAs demonstrated high 
sensitivity and specificity which is an essential first step to be considered a potential 
biomarker.  
Further studies were performed surrounding the expression and function of miR-
let-7b that effects GCs and cumulus cells. As previously stated, Scalici et al. (2016) 
found lowered levels of miR-let-7b in PCOS women, and other researchers have 
postulated that this may lead to the abnormal folliculogenesis that is seen in PCOS. Cao 
et al. (2015) showed that miR-let-7b could play a role in follicular development via 
regulation of TNF-β, also known as tumor necrosis factor-beta. TNF-β is a protein that 
arises from the lymphotoxin alpha (LTA) gene and has a variety of important roles from 
providing immunity to cell survival, proliferation, and differentiation (Bauer et al., 2012).  
According to a study performed by Zhang et al. (2017) miR-let-7b can potentially 
regulate TGF- β via Activin Receptor-1 and Smad 2/3. SMAD proteins act as modulators 
that are involved in many signaling pathways. TGF-β and its receptor recruit SMAD and 
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activate the SMAD anchor for receptor activation (SARA) protein. In response, this 
protein is phosphorylated by the TGF-βreceptors (Kim et al., 2009). The phosphorylation 
stimulates the dissociation of SMAD and SARA. Thereafter, exposing the nuclear import 
sequence which allows the SMAD to enter the nucleus and bind to a target gene along 
with other proteins (Qin et al., 2001). So far, it seems from the variety of published 
studies that miR-let-7b affects cell survival and proliferation, but there is no consensus as 
to which pathway.  
Another study demonstrated by Miles et al. (2012) observed miR-let-7b and how 
it functions by suppressing Myc. Myc is a proto-oncogene that encodes an important 
protein involved in stimulating cell proliferation and can promote cell cycle progression 
(Genetics Home Reference, 2017). Studies have illustrated that miR-let-7b has many 
different targets and is involved in multiple pathways. This led researchers to conjecture 
that miR-let-7b contributes to the reproductive abnormalities that are seen among 
subjects with PCOS. Based on this, miR-let-7b shows promise as a potential biomarker, 





Up to this point, the selected miRNAs have been focused on either the endocrine 
or metabolic aspect of PCOS (Villa & Pratley, 2011). This selection makes sense in light 
of the result of the heavy involvement of hormones like testosterone and estrogen which 
contribute to irregular follicle development as well as other symptoms like hirsutism 
(Xue et al., 2018). Also, IR is a common symptom of PCOS. Many studies were directed 
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towards adipocytes and their differentiation to explain what may lead to IR (Rocha et al., 
2019). Logically, this intrigued researchers to look for possible miRNAs involved in 
these processes. However, thinking long-term, patients want a diagnosis without many 
invasive procedures involved. For example, a blood test would be ideal in trying to 
minimize invasiveness. So identifying miRNAs in the serum that might aid in explaining 
the pathophysiology of PCOS (Arancio et al., 2018).  
Of interest to many researchers is the family of miR-29a. This is because it has 
been strongly associated with being in the serum and therefore easier to measure levels of 
this miRNA compared to the ovarian tissues and adipocytes (Bagge et al., 2012). 
Sorenson et al. (2016) designed a study with 49 women with PCOS: 19 expressed 
hyperandrogenism, whereas 30 had normal levels of androgens, and 21 women who did 
not have PCOS. Afterwards, miRNA levels were estimated using PCR. The results 
showed that among all PCOS women there was a statistically significant decrease in 
miR-29a. Other miRNAs found were: miR-24, miR-151, & miR-574. All of the listed 
miRNAs via TargetScan are involved in the regulation of cell proliferation and 
biosynthetic processes as well as negative transcription. With respect to miR-29a, a 
certain form, miR-29a-3p, effected androgen receptor transcript levels and protein kinase 
B (AKT2) levels.  
AKT along with phosphatidylinositol 3-kinase (PI3K) is involved in a signaling 
pathway that promotes cell survival and growth (Martini et al., 2014). This pathway is 
highly regulated and can communicate with other signaling pathways. One of the many 
ways this pathway can be activated is via insulin or IRS-1. There is a negative feedback 
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loop where S6K1 phosphorylates IRS-1 and prevents it from binding to receptor tyrosine 
kinases (RTK). AKT is located in the cytosol and is inactive until phosphorylation occurs 
by multiple proteins such as: phosphoinositide-dependent kinase 2 and integrin-linked 
kinase among others (Martini et al., 2014).   Problems with this pathway has been linked 
to many diseases of interest to the PCOS researchers like type II diabetes as well as IR 
(Nandi et al., 2014). These are the same results that Sorenson et al. (2016) came across. 
In addition, they saw an impaired glucose-stimulated insulin secretion of β cells. As 
mentioned previously, IR & type II diabetes are closely linked to the dysfunctional 
features of PCOS.  
These results were further supported and confirmed by Arancio et al. (2018). 
Even though their results concluded that miR-155 might be a better biomarker than miR-
29a, the target genes and pathways that miR-29a effects were similar. These researchers 
witnessed a negative correlation between androstenedione concentrations and miR-29a. 
Research demonstrated that women with high levels of androstenedione had an adverse 
metabolic phenotype (Lerchbaum et al., 2014). As discussed above, Sorenson et al. 
(2016) also saw similar results, but with androgen receptors, however if we take both 
results we can extrapolate that miR-29 can play a role in leading to hyperandrogenemia 
among women with PCOS. 
The evidence gathered so far touches upon the metabolic component and 
illustrates that PCOS is not only endocrinological in nature but also metabolic as well. 
miR-29a is a strong contender for being a potential biomarker for PCOS. It has been 
associated with IR and type II diabetes that PCOS women are at a higher risk of 
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developing. It is worth reiterating that to deem a biomarker credible there needs to be 
more concrete evidence establishing a mechanism prior to moving onto a larger sample 
size. Further experimentation needs to be performed about which forms of miR-29a 




Altering levels of miRNAs among women with PCOS have been associated with 
diabetes, IR, and inflammation (Dou et al., 2013). The pathway related to IR in terms of 
PCOS is not fully known and studies are still being conducted to figure it out. As 
mentioned previously, miR-155 was also a contender as a potential biomarker (Sirotkin et 
al., 2010).  This miRNA was chosen because studies have shown it has a role in 
regulating insulin and is involved in chronic inflammation. Cirillo et al. (2019) studied 
miR-155 among other selected miRNAs to see if there is a possible correlation between 
insulin, IL-6, and 17-beta estradiol.  
Upon collection of samples, techniques were performed to filter out the selected 
miRNAs. The preliminary analysis measured levels of the selected miRNAs that were 
chosen to study, Cirillo and colleagues (2019) illustrated that miR-155 were significantly 
upregulated in both GCs and follicular fluid in subjects with PCOS. Also, miR-155 is 
correlated with HMGB1 and insulin concentrations. A target gene analysis was 
performed and some notable genes that miR-155 was associated with were: KRAS, 
PAK2, NFKB1, and FOXO1. FOXO1 is of particular interest because previous studies 
have established that it is an important transcription factor that plays a role in regulating 
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gluconeogenesis and glycogenesis via insulin and promotes adipocyte differentiation 
(Nakae et al., 2003). This study was able to illustrate that insulin sensitivity within the 
ovary is a major factor when investigating PCOS.  
Previous literature explored the possible roles of miR-155 in cancer cell 
proliferation, invasion, and metastasis (Liu et al., 2018). However, increasing studies are 
exploring the potential role that miR-155 plays in the pathophysiology of PCOS such as 
Xia et al. (2020). Xia and colleagues (2020) designed an experiment to study the effects 
and regulatory mechanisms by which miR-155 acts. Utilizing similar techniques to other 
researchers in the field, the results demonstrated that there was a significantly higher 
level of expression of miR-155 in PCOS women compared to control. Levels of cyclin 
D1, p53, and p21 were measured along with levels of miR-155 to see whether or not they 
were correlated. Results showed levels of cyclin D1 were increased, whereas p53 and p21 
were reduced. As a result, this promotes cell cycle proliferation. This hypothesis is 
further supported when cells were transfected with an miR-155 inhibitor, Xia et a. (2020) 
saw apoptosis rates had increased. Once this was established, it made sense to study 
PI3K/AKT and JNK signaling pathway to see if programmed cell death protein4, 
PDCD4, had an effect on this pathway (PDCD4 Gene - NCBI, 2020). The findings 
resulted in the following conclusion: PDCD4 was a target of miR155 and down-regulated 
by miR-155 in the process of PCOS and this supports increased cell proliferation.  
In conclusion, miR-155 is a promising biomarker that needs more research 
elucidating the cell proliferation and insulin sensitivity pathways. It is worth noting that 
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the experiments performed thus far have shown strong evidence, but future studies need 
to implement a larger sample size. 
Table 2. Summary of miRNAs discussed with expression levels, where they are located, and 
possible target genes. 
miRNA Level of Expression Location Target Gene(s) 
miR-145 Down-regulated GC IRS-1 
mirR-200b & miR-
200c 
Up-regulated GC PTEN 
miR-93 Up-regulated GC, Follicular Fluid CDKN1A 
miR-223 Up-regulated Adipocyte GLUT4 
miR-25 Up-regulated Adipocyte MCM7 
miR-21 Up-regulated Serum, Adipocyte TGFBR2 
miR-29a Down-regulated Serum AKT 
miR-155 Up-regulated Serum, GC FOXO1, PDCD4 
miR-320 Down-regulated Follicular Fluid ET-1 





There are several proposed biomarkers for polycystic ovarian syndrome, many of 
them require further elucidation of the mechanisms that might contribute to the 
pathophysiology of the disease (Ma et al., 2007). Throughout this paper, I have explored 
ten miRNAs as listed and summarized in Table 2. Through this review of current PCOS 
literature, I have been able to come to several conclusions regarding which miRNA offers 
the most promise based on the results of these studies. In this section, I will discuss the 
results of the research described previously and then hope to provide some novel 
conclusions.  
 Granulosa cells within the ovary have been the focus of much research as 
scientists works to understand pathophysiology of PCOS. Advancements in 
understanding what role the GCs play in the hormonal pathway have allowed for the 
successful identification of plausible miRNAs that might regulate this pathway and 
contribute to PCOS (Sirotkin et al., 2009). By determining where the miRNA is able to 
act upon scientists are one step closer in identifying a promising biomarker as well as a 
therapeutic agent. Human trials are currently in the process of discovering new miRNAs 
as well as demonstrating that these miRNAs are not just restricted to one pathway but can 
have an effect on multiple pathways (Wissing et al., 2014). So far, the reports have 
described multiple genes that a miRNA can regulate. Almost every miRNA discovered in 
GCs I have reviewed not only affects ERα and ERβ receptors, but also the metabolic 
aspect of PCOS (Jakimiuk et al., 2002). These results displayed establish the fact that 
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PCOS is most definitely an endocrine and metabolic disorder and discovering a 
biomarker that regulates both aspects would be a good start.  
 There are still improvements that must be made to the type of studies being 
conducted to demonstrate a plausible miRNA before it is considered a good biomarker. 
Rupaimoole et al. (2011) reported that one of the key aspects of identifying miRNAs is 
that they have a long half-life so the levels are accurately represented. The researchers 
provide several solutions like chemically modifying the miRNAs, but this falls short 
because this may lead to off-target effects and degradation can lead to toxic by-products 
being made. These are areas that need to be further perfected to optimize and produce 
viable biomarkers. Additionally, more research needs to be targeted at not only 
elucidating mechanisms by which miRNAs regulate pathways, but also looking at larger 
sample sizes. It is clear after viewing the results of these experiments that miRNAs such 
as miR-93 show more promise compared to miR-145, miR-200b or miR-200c. There also 
needs to be consistent results showing that levels of miR-93 are up-regulated among 
women with PCOS, because some research that has been published is contradictory and it 
becomes difficult to establish a baseline (Naji et al., 2017). Overall, GCs offer great 
promise in finding potential biomarkers for PCOS.  
Adipocytes and its tissues, like GCs, produced and resulted in the discovery of 
more miRNAs that can function as future biomarkers for PCOS. There is still a great deal 
of research that needs to be completed before these experimental approaches become 
clinically applicable. As research has demonstrated PCOS patients are more at risk of 
developing type II diabetes and IR. However, a problem with this is that scientists are 
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unsure of the pathways that lead to impaired insulin signaling and insulin resistance 
(Wang et al., 2019). Many researchers like Samuel and Shulman (2012) know it is not 
one single pathway but a common pathway that acts diversely depending on the type of 
tissue. Another issue that needs to be examined is that much of the research has linked 
obesity as being a clinical manifestation of PCOS, however, there are also non-obese 
patients with PCOS, and when trying to identify miRNAs in adipocytes, the miRNAs 
selected still need to show a statistically significant result in both groups.  A concern is 
that these miRNAs still need to be valid among patients who are non-obese as well. 
Research focused on IR and insulin signaling pathways as well as adipocyte 
differentiation among subjects with PCOS versus those who did not and realized that 
different expression of miRNAs was seen amongst both groups (Delitala et al., 2017). 
Scientists found miR-21 to regulate differentiation in adipocytes via manipulation of 
TGF-β pathway. A possible avenue to find a reliable biomarker might also be to observe 
the differentiation process to see if that can partially explain PCOS.  
Still, even in light of all these problems, the current research is promising in that 
the miRNAs that were identified offer a great deal of promise for the future, in not only 
trying to diagnose PCOS, but for shedding light on IR and insulin signaling pathway as 
well. Many of the researchers used a TargetScan to try and associate the miRNAs of 
interest with potential genes that they affect. For example, miR-223 was associated with 
the gene GLUT4 which research has established is critical for allowing glucose to be 
taken in by adipocytes (Chuang et al., 2015). The results showed that the protein levels of 
GLUT4 were decreased because miR-223 was bound to the 3’-UTR of the GLUT4 
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mRNA and prevented GLUT4 from being translated among patients with PCOS (Chuang 
et al., 2015). However, as mentioned previously there needs to be more studies conducted 
to ensure that this is a reliable measurement across all patients diagnosed with this 
disease. The results are far from conclusive and there are still improvements that need to 
be made before miR-223 can be used to diagnose patients with PCOS.  
Much research has been dedicated to follicular fluid. This intrigued me the most 
and I found quite informative that miRNAs were in the follicular fluid. Many researchers 
have dedicated a great deal of time and effort to explore the follicular fluid and inform 
the scientific community that it is more than just an area where metabolites and nucleic 
acids are stored, but also provides pertinent information like the quality and growth of the 
ovary (Butler et al., 2019). Although they have produced promising results, for the most 
part, just demonstrated the selected miRNAs are involved with major growth and 
development pathways such as MAPK, PI3K-AKT, and TGF-β. Many of the current 
researchers now hypothesize that cell proliferation and growth play an influential part in 
explaining the etiology of PCOS (Song et al., 2015). This is because research based on 
the selected miRNAs show that many of these target genes that were associated were 
with these pathways. Using this knowledge in combination with what we already know 
about PCOS might lead us in further trying to identify prospective miRNAs. 
Coincidentally, there were numerous studies that studied the GCs and cumulus cells 
proliferation and apoptosis rates by utilizing selected miRNAs. The most notable miRNA 
that researchers came across in the follicular fluid is miR-let-7b, because not only is it 
associated with TNF-β but also has been associated with a proto-oncogene Myc which 
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can also aid in informing researchers not only about PCOS but also lymphomas (Cao et 
al., 2015).  
The serum is another a location where possible miRNAs were found, but more 
importantly it is worth noting that it is the most readily accessible area in term of human 
testing. Considering that many diagnostic and lab tests look out for patient’s preferences 
to be minimally invasive, this would be a favorable area of research for PCOS. 
Unfortunately, with the research that is currently available there were few miRNAs that 
are considered promising (Arancio et al., 2018). Much of the research regarding PCOS 
and possible miRNAs have been studied in ovarian tissues and its surroundings as well as 
adipocyte tissues. One of the more prominent miRNAs that were discovered was miR-21. 
It has received attention due to the fact that it has been linked in a variety of cancers, but 
also has recently received attention because it has been implicated in PCOS. Various 
studies have supported that miR-21 has been associated with TGFBR2 and it is involved 
in once again cellular growth and survival (Carletti et al., 2010). Further studies need to 
be done in this area of PCOS and provide valuable information, however, there are small 
amount of miRNAs in a given blood volume and this is an important perspective to 
consider when moving forward.  
After careful analysis of the current literature, it appears that GCs, adipocytes, and 
the follicular fluid hold the most promise in trying to identify miRNAs as biomarkers for 
PCOS in the years to come. Not only do these areas have a multitude of selected miRNAs 
that were studied, but they also tried to explain the underlying etiology of PCOS by 
looking into the endocrine and metabolic aspects. Aside from having multiple gene 
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targets for many of these miRNAs, all the gene targets that were found seem to be 
clustered under one of three groups: production/synthesis of hormones, IR and insulin 
signaling, and cell proliferation and survival. As for the serum, this compartment might 
be able to give us insight but until better qualitative and quantification methods are 
introduced it might be considered an alternative place to look. As much promise as the 
miRNAs hold for the future, it will take a while before human subjects are recruited to 
diagnose PCOS based on biomarkers (Y. Zhang et al., 2017). A common theme across 
studies performed to find miRNAs associated with PCOS is that they were preliminary 
studies: in trying to figure out a well explained mechanism and the sample size of the 
studies was not enough to move onto the next phase.  
It is my personal hope, as well as thousands of people afflicted with this horrible 
syndrome that more progress is made in the years to come. Because science has seen the 
potential of miRNAs, especially in the field of oncology, it is possible that it will not be 
too long until miRNAs are found within the realm of PCOS. All research needs is one 
breakthrough which will allow an accurate diagnosis of PCOS and simultaneously will 
also provide a permanent treatment as well. By taking a hard look at the current literature 
and identifying the most promising miRNAs, we can allocate resources and efforts to 
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